Real-World Effectiveness of Obeticholic Acid in Patients With Primary Biliary Cholangitis

摘要

Randomized studies have shown that UDCA, available since 1990, enables patients to live longer without liver transplantation.1,2 In 2016, OCA was approved by the FDA as a second-line treatment for the many patients who do not respond to UDCA. OCA is a potent farnesoid X receptor agonist and a semi-synthetic derivative of chenodeoxycholic acid. Although OCA has been studied in clinical trials,3 data on its real-world effectiveness are limited.